Partnered with the oncology senior leadership strategy team and guided prioritization across the oncology portfolio. Restructured and improved prioritization process by creating an objective method and annual assessment. Ran clinical trial benchmarking and PTRS (probability of technical and regulatory success) exercises with project teams that drove more objective discussions, improving transparency and believability of risk assessments.
Led the global commercial launch of the first compound (Sylvant, siltuximab) indicated for an ultra-orphan indication (Multicentric Castlemans Disease) treated by hematologists . Co-led global commercial launch of the first in class monoclonal antibody for the treatment of multiple myeloma (Darzalex, daratumumab) that achieved >$1B in first year sales. This included creation of a brand vision and messaging for both compounds that changed the treatment paradigm in the respective diseases.
Deb Alper is a global marketing leader who blends customer focused insights across departments including Research, Development, Regulatory, Medical Affairs, Market Access, Supply Chain, Project Management, and Communications and identifies the most effective and efficient methods that drive consensus and solutions. Recognized as a trusted advisor, managing end to end commercialization, from discovery through launch, resulting in optimal patient outcomes.
Oncology, Hematology, Rare Diseases